Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-03
2006-10-03
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S350000
Reexamination Certificate
active
07115560
ABSTRACT:
The invention provides methods of modulating gastric acid secretion by administering an amount of a prokineticin receptor antagonist effective to alter one or more indicia of gastric acid secretion, wherein the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ ID NO:3, which includes (a) the 10 conserved cysteine residues of SEQ ID NO:3, and (b) from 0 to 9 of amino acids 78 to 86 of SEQ ID NO:3, wherein amino acids 1 to 6 of the antagonist do not consist of amino acids AVITGA (SEQ ID NO:21). In another embodiment, the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ ID NO:6, which includes (a) the 10 conserved cysteine residues of SEQ ID NO:6, and (b) from 0 to 4 of amino acids 78 to 81 of SEQ ID NO:6, wherein amino acids 1 to 6 of the antagonist do not consist of amino acids AVITGA (SEQ ID NO:21).
Carlson Karen Cochrane
DLA Piper Rudnick Gray Cary US LLP
The Regents of the University of California
LandOfFree
Methods for modulating gastric secretion using prokineticin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for modulating gastric secretion using prokineticin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for modulating gastric secretion using prokineticin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3695633